哌拉西林/他唑巴坦临床应用30例分析  

30 Cases of the Clinical Use of Tazocin

作　　者：孙荣青[1] 冯敏[1] 杜玉明[1] 王红民[1] 许爱国[1] 

机构地区：[1]郑州大学第一附属医院ICU,郑州450052

出　　处：《中国临床医学》2004年第5期878-879,共2页Chinese Journal of Clinical Medicine

摘　　要：目的 :总结哌拉西林 /他唑巴坦 (特治星 )治疗ICU病人细菌性感染的经验并评价其疗效及不良反应。方法 :采用随机对照 ,设实验组及对照组 (各 30例 )。实验组给予特治星 4 .5g/ 8h ;对照组给予泰能 0 .5 g/ 8h ,分别加入 10 0ml生理盐水中静脉滴注 ,30min内滴完 ,疗程 7～ 14d。结果 :试验组临床治愈率为 80 % (2 4 / 30 ) ,有效率为 93% (2 8/ 30 ) ,细菌清除率为 92 .4 %(2 4 / 2 6 )。而对照组分别为 83% (2 5 / 30 ) ,93% (2 8/ 30 ) ,93.3% (2 6 / 2 8)。经统计学处理两组无显著差异 (P >0 .0 5 )。两组不良反应发生率为 6 .6 %。结论 :派拉西林 /他唑巴坦抗菌谱广 ,不良反应发生率低。Objective: To summarize the therapeutic experience of tazocin on Bacterial infection of the ICU patients and to evaluate the effect and safety of tazocin. Methods: 60 patients were divided into the treatment group (30 cases) and the control group(30 cases) randomly. The treatment group was treated with tazocin with a dose of 4.5g/8h. The control group was treated with Tienam with a dose of 0.5g/8h. Both of the two drugs were added into 100ml Saline to infusion on patients during 30 minutes. The course was 7 to 14 days. Results: The treatment group showed a healing rate of 80% (24/30), effective rate of 93% (28/30), and bacteria clearance of 92.4% (24/26). The Control group showed a healing rate of 83% (25/30), effective rate of 93% (28/30), and bacteria clearance of 93.3% (26/28). There were no statistic differences between two groups (P>0.05). The total adverse reaction incidence was 6.6%. Conclusion:Piperacillin/tazobactam has a wide antimicrobial spectrum and a low adverse reaction incidence. The effect of tazocin in clinical application should be approved.

关 键 词：临床应用 对照组 哌拉西林/他唑巴坦 不良反应 特治星 发生率 治疗 目的 经验 有效率 

分 类 号：R978[医药卫生—药品] R563.1[医药卫生—药学]